STAT· @statnews · X·· 2 小时前精选AI 评分60
AI 导读
Life Biosciences 的细胞重编程药物已用于三名青光眼患者，未出现严重不良事件。这是该理论首次在人体中测试，即通过给予精确的蛋白质组合使细胞恢复到更年轻的状态。
推荐理由
三名青光眼患者接受细胞重编程药物且未出现严重不良事件，是这一细胞年轻化理论首次进入人体试验的早期信号。
正文
Three glaucoma patients have received Life Biosciences' cellular reprogramming drug, with no serious adverse events.
The drug is the first human test of the theory that giving a precise cocktail of proteins could rejuvenate cells back to a younger state. https://trib.al/IK5VuZe
来源：STAT · x.com